📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
NEUTRAL
score: 0.17
SENTIMENT
BULLISH
TOTAL VIEWS
4
RECENT COVERAGE · 4 ARTICLES
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite Pharmaceuticals (CANF) reported positive interim Phase 2a data for namodenoson in advanced pancreatic cancer, marking a...
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Pharmaceuticals has achieved Japanese patent allowance for Namodenoson, its anti-obesity compound candidate. This regulatory...
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite BioPharma (CANF) has published peer-reviewed research validating its lead compounds, Piclidenoson and Namodenoson, across...
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite Pharmaceuticals announced participation at the BIO International Convention 2026, where management will present its late-stage...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice